A biomarker identified by integrated bronchoalveolar lavage fluid and lung tissue lipidomics mitigates respiratory syncytial virus infection
Journal of Pharmaceutical and Biomedical Analysis · 2025
DOI: 10.1016/j.jpba.2025.117010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2025. Verfasst von Shaodong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Bronchoalveolar Lavage Fluid, Lung. Die Arbeit nennt 27 Literaturangaben. Gefördert von: the 2024 World Traditional Chinese Medicine Science and Technology Special Project, Jiangsu Provincial Traditional Chinese Medicine Science and Technology Development Plan Youth Talent Project.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a highly pathogenic respiratory virus that severely impacts infants under 2 years, adults over 60, and immunocompromised individuals. Currently, no safe, low-toxicity, or cost-effective therapy is available for RSV. Research indicates that RSV infection disrupts pulmonary surfactant lipid metabolism. Through lipidomic analysis of bronchoalveolar lavage (BAL) fluid and lung tissue, we observed an increase in most phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), while all phosphatidylglycerols (PGs) decreased. Additionally, all lysophospholipids in lung tissue increased. Among the altered lipids, 27 showed significant changes in both BAL fluid and lung tissue, including 15 phospholipids (7 PCs, 5 PEs, 3 PGs, and 1 phosphatidylinositol (PI)). From the decreased PGs, we identified an active lipid, PG 16:0-18:2, which correlated strongly between BAL fluid and lung tissue. Further studies confirmed that PG 16:0-18:2 significantly reduces viral load, mitigates RSV-induced lung damage, and reduces pulmonary inflammation. In vitro experiments demonstrated that PG 16:0-18:2 directly inhibits RSV replication and proliferation in epithelial cells. These findings suggest that PG 16:0-18:2 could serve as an effective and non-toxic antiviral agent, offering a promising complementary approach to RSV treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Institute of Pediatrics, Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Electronic address: penglinxiu@njucm.edu.cn.
Förderung
- the 2024 World Traditional Chinese Medicine Science and Technology Special Project
- Jiangsu Provincial Traditional Chinese Medicine Science and Technology Development Plan Youth Talent Project
Zitieren
APA
Wang, S., Lin, L., Lei, Y., Li, Q., & Peng, L. (2025). A biomarker identified by integrated bronchoalveolar lavage fluid and lung tissue lipidomics mitigates respiratory syncytial virus infection. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2025.117010
Vancouver
Wang S, Lin L, Lei Y, Li Q, Peng L. A biomarker identified by integrated bronchoalveolar lavage fluid and lung tissue lipidomics mitigates respiratory syncytial virus infection. Journal of Pharmaceutical and Biomedical Analysis. 2025. doi:10.1016/j.jpba.2025.117010
BibTeX
@article{Wang2025,
author = {Wang, Shaodong and Lin, Lili and Lei, Yueyue and Li, Qiuyuan and Peng, Linxiu},
title = {A biomarker identified by integrated bronchoalveolar lavage fluid and lung tissue lipidomics mitigates respiratory syncytial virus infection},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2025},
doi = {10.1016/j.jpba.2025.117010}
}
EUVIMED